RightEye’s eye-tracking system gets FDA clearance, based on competitor’s technology
Bethesda, Maryland-based RightEye has received a 510(k) clearance for its EyeQ eye-tracking platform using competitor SyncThink's technology as a predicate device.
Neuraly launches with $36 million Series A to develop neurological disease drug
Nature Medicine mouse study shows once-weekly GLP-1 receptor agonist slowed Parkinson's disease progression.
presented by
Your Guide to the Best Vein Clinics in Orlando
Your varicose or spider veins may indicate an underlying problem, so finding the right vein specialist is crucial. Discover the best vein clinics in Orlando.
Verge Genomics raises $32 million in Series A for AI-discovered drugs
San Francisco-based firm, focusing on Parkinson's disease and amyotrophic lateral sclerosis, has raised $36 million to date.
Appello Pharmaceuticals nets $10.5 million in Series A funding for Parkinson’s drugs
The company will use the funding to develop mGlu4 PAMs licensed from Vanderbilt University.
Wearables build momentum for Parkinson’s disease research
A study by the Michael J Fox Foundation using Verily's Study Watch underscores the increasing use of wearables not only for Parkinson's disease research but also to identify ways to more accurately diagnose the neurodegenerative condition and to assess the impact of medication and other types of treatment interventions.
FDA-cleared wearable for Parkinson’s disease patients gets $6M+ funding boost
The funding is aimed at commercializing the device in the U.S. and other markets, according to the company's website citing The Australian Financial Review.
presented by
Navina’s AI Copilot Eases the Value-Based Burden, Study Shows
A new independent study from Phyx Primary Care’s Innovation Lab points to measurable improvements in physician burnout, documentation efficiency, and key VBC metrics among primary care practices.
Boston Scientific gives deep brain stimulation a new look
Boston Scientific's neurostimulation device Vercise is built on cochlear implant technology, allowing it to modulate impulses between multiple contacts.
Do caregivers need a Parkinson’s disease simulation device to experience empathy?
Do doctors need a shot of empathy? Researchers at a Canadian digital healthcare marketing company think so, and say they can administer it wirelessly.
FDA allows 23andMe to reintroduce 10 genetic health risk reports for Parkinson’s, Alzheimer’s, and more
Some 3 1/2 years after having its hand slapped, 23andMe has received a green light from the FDA to market 10 direct-to-consumer genetic health risk reports for conditions such as Parkinson’s, late-onset Alzheimer’s, and celiac disease.
Newly-approved Parkinson’s drug isn’t that novel
Championed as the first new chemical entity approved for Parkinson's disease in over a decade, safinamide is really part of an existing family of drugs that have been on the market for decades.
presented by
The Top 5 Home Care Franchise Opportunities in the U.S.
The home care industry is booming. As Baby Boomers age and more families seek in-home solutions for loved ones, demand for home care services is at an all-time high.
What’s the regulatory framework for neuroprosthetic devices?
Companies developing deep brain stimulation and other neurostimulator technologies that can control and communicate signals to and from artificial body parts (i.e. limbs, eyeballs) are the latest players in the medical device sector.
Targeted Facebook ads slash recruitment costs for Michael J. Fox Foundation
The average cost of recruiting a trial subject via the targeted Facebook ads was $35, 96 percent less than the $800-per-person average through other means for the Michael J. Fox Foundation study.
Morning Read: St. Jude’s deep brain stimulation system launches in Europe
Also, Bob Abraham, Pfizer's head of oncology research and development, talks about the ups and downs of drug development and Philadelphia becomes the first major city to pass a soda tax.
IBM, Pfizer team on remote monitoring for Parkinson’s care
IBM and Pfizer will build a IoT ecosystem to measure the health and quality of life of Parkinson's patients.
Morning Read: FDA panel approves Acadia’s Parkinson’s disease treatment
Also, Aveo Pharmaceuticals will pay $4 million to settle charges with the SEC, and EMED Technologies said today that it is seeking a federal court injunction against competitor Repro-Med Systems.